Archive
All News
Every briefing, headline, and filing we've published, newest first.
The WeekPharmaceutical Technology ↗
Lilly's drug could cut the number of injections each patient needs by 85%.…
The WeekSTAT News ↗
Urologic oncologists who treat prostate cancer are split over the benefits of focal therapy compared to tradit…
The WeekBioPharma Dive ↗
Pasatru's approval sets up a market battle in a rare indication where the only available treatment has generat…
The WeekPharmaVoice ↗
Six industry leaders share the scientific papers they keep circulating, spanning transplants, MASH, cancer, re…
The WeekFiercePharma ↗
Boehringer Ingelheim has continued its rise up patient groups' ranking of rare disease companies, adding to la…
The WeekFierceBiotech ↗
TScan has told Fierce that its pipeline strategy remains unchanged despite Amgen walking away from a Crohn's d…
The WeekBriefing
FDA approved Pasatru for adults with fibrodysplasia ossificans progressiva on August 19. The filing points to …
The WeekSTAT News ↗
Between success with a pancreatic cancer drug and now success with an mRNA neoantigen vaccine, it has been a b…
The WeekPharmaceutical Technology ↗
SandboxAQ has introduced AQPotency, a LQM designed to virtually screen and predict the potential of drug candi…
The WeekBioPharma Dive ↗
Heidi Overton, a medical doctor and veteran of the America First think tank, currently serves as deputy direct…
The WeekPharmaVoice ↗
Heidi Overton, a medical doctor and veteran of the America First think tank, currently serves as deputy direct…
The WeekPharmaVoice ↗
As Eli Lilly and Novo Nordisk race for share, surveys show affordability and prescribing preferences may help …
The WeekFiercePharma ↗
Revance has appointed Ulta Beauty and Procter & Gamble alum Janelle Wichmann as its new chief marketing of…
The WeekFierceBiotech ↗
Oncology R&D organization Sarah Cannon Research Institute (SCRI) announced a collaboration with Merck &…
The WeekBriefing
Sanofi’s Blueprint cuts look like standard integration, but investors will watch for a broader reset
Sanofi is cutting 229 Blueprint Medicines roles and closing two Cambridge offices after its $9.1 billion acqui…
The WeekSTAT News ↗
The accrediting group for schools of public health is weighing the removal of language that specifically requi…
The WeekBioPharma Dive ↗
The Alesta buyout helps restock BioMarin's pipeline with an asset it says could "reach our largest addressable…
The WeekFiercePharma ↗
The phase 3 misstep could undercut EyePoint's ambition to displace Eylea as the high-value treatment of choice…
The WeekFierceBiotech ↗
Leo Pharma is sticking to its mission of strengthening its pipeline in 2026, penning a $435 million deal for a…
The WeekPharmaVoice ↗
Can Michael Halstead replicate the controlled growth he pulled off at Intra-Cellular Therapies in mental healt…
The WeekBriefing
FDA cleared Lantheus’ Alzheimer’s PET imaging agent Tauklarify. The decision lands as Lantheus moves toward an…
The WeekDrug Channels ↗
By Greis Kapexhiu and Adam J. Fein, Ph.D. In June 2025, the FDA announced that CAR-T therapies would no longer…
The WeekPharmaceutical Technology ↗
New guidance from NICE provide a framework for UK care providers using finerenone to manage the treatment of c…
The WeekSTAT News ↗
Colorado biotech Enveda reports preliminary results on a drug to help people maintain weight loss after GLP-1 …
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.